Xuhong Min

机构：Anhui Provincial Hospital, Xi'an Chest Hospital · ORCID：0000-0001-6498-3278

发表论文 8 篇 · 总被引 92 次 · h-index 5

代表论文

• Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study. (2022 · Journal of Clinical Oncology · 被引 35)
• First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial (2025 · 癌症：英文版 · 被引 21)
• Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial (2023 · Signal Transduction and Targeted Therapy · 被引 18)
• CAMPASS: Benmelstobart in combination with anlotinib vs pembrolizumab in the first-line treatment of advanced non-small cell lung cancer (aNSCLC)—A randomized, single-blind, multicenter phase 3 study. (2025 · Journal of Clinical Oncology · 被引 8)
• Evaluating efficacy and safety of a novel registration-free CT-guided needle biopsy navigation system (RC 120): A multicenter, prospective clinical trial (2024 · Lung Cancer · 被引 7)
• R-ALPS: A randomized, double-blind, placebo-controlled, multicenter phase III clinical trial of TQB2450 with or without anlotinib as maintenance treatment in patients with locally advanced and unresectable (stage III) NSCLC without progression following concurrent or sequential chemoradiotherapy. (2025 · Journal of Clinical Oncology · 被引 3)